NCT04356742View on ClinicalTrials.gov

Efficacy and Safety of Dapagliflozin When Added to Ongoing Metformin and Evogliptin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control

PHASE3CompletedINTERVENTIONAL
Enrollment

198

Participants

Timeline

Start Date

May 26, 2020

Primary Completion Date

February 23, 2022

Study Completion Date

February 23, 2022

Conditions
Type 2 Diabetes
Interventions
DRUG

Dapagliflozin 10mg

Dapagliflozin 10mg, orally, once daily, up to 24weeks

DRUG

Placebo

Dapagliflozin Placebo, orally, once daily, up to 24weeks

DRUG

Evogliptin 5mg

Evogliptin 5mg, orally, once daily for background therapy

DRUG

Metformin≥1000mg

Metformin≥1000mg, orally, daily for background therapy

Trial Locations (1)

Unknown

The Catholic University of Korea Bucheon St. Mary's Hospital, Bucheon-si

All Listed Sponsors
lead

Dong-A ST Co., Ltd.

INDUSTRY

NCT04356742 - Efficacy and Safety of Dapagliflozin When Added to Ongoing Metformin and Evogliptin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control | Biotech Hunter | Biotech Hunter